Nancy O'Hagan, CFCF Founder and President, blogs on the costs of medical research. 

Lauren Erb, CFCF Vice President, blogs on participating in the Blackwood Family Tri For Life Triathlon.

Read Lauren's blog

To learn more about the Blackwoods and how they are fighting for a cure:
www.blackwoodcaring.com

CFCF introduces "Ask the Doctor." 

Do you have questions about science or clinical treatment?  Ask the Doctor!  This month Dr. Kulke is on-call.

Dr. Matthew Kulke of the Dana Farber Cancer Institute and co-Chairman, CFCF Board of Scientific Advisors, recently highlighted progress in the field of neuroendocrine tumor research.
Read Dr. Kulke's blog

To submit your questions please email:
Responses to the most frequently asked questions will be in the next E-Update.  E-mails that ask for medical advice about an individual's personal medical situation cannot be answered.  Please see CFCF's User Agreement for more information

The authors state:

"In summary, we have identified a novel set of genes that may play a role in the pathogenesis and progression of PNETs and GI-NETs. Our results reveal a correlation with the WHO histologic classification on a molecular level... By improving the molecular classification of these tumor subtypes, we may ultimately enhance our ability to predict tumor behavior, provide important new insights into the molecular biology and tumor pathogenesis, and design the next generation of targeted therapies."

 
For the full article:

The Caring for Carcinoid Foundation (CFCF) reports all research progress by our funded scientists.  This policy is based on our commitment to transparency and accountability.
 
CFCF-funded scientists are making rapid progress in unlocking the genetic causes of carcinoid and developing novel, targeted therapies.
 
We invite you to review their exciting research progress.

Join Team CFCF to raise money for carcinoid and NET research.

CFCF still has 20 spots remaining for the sold out Bank of America Chicago Marathon.  Please invite your friends and family to join Team CFCF and run to a cure!

To register please go to:
CFCF Chicago Marathon Registration

Visit Team CFCF Page

Team CFCF is sponsored by the generous support of Molecular Insight Pharmaceuticals.

Molecular Insight Pharmaceuticals (MIP) is supporting team CFCF in the Bank of America Chicago Marathon and Swim Across America Boston Harbor Swim. 

Why is Molecular Insight Pharmaceuticals supporting carcinoid and related NET patients?

Molecular Insight specializes in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve patient care by addressing significant unmet medical needs.  The Company is committed to improving healthcare for patients with life-threatening diseases.

Molecular Insight is developing Azedra, a novel targeted radiotherapeutic, for the treatment of neuroendocrine tumors. Azedra is based on the known 1-131 MIBG molecule, a targeted radiotherapy that has been researched internationally with evidence that it is effective in treating several types of neuroendocrine tumors.  Azedra is optimized by the Company's proprietary Ultratrace™ technology.  Ultratrace allows Molecular Insight to provide patients with the benefits of Azedra free of cold contaminants, which are unnecessary, nonradioactive targeting molecules present in the traditional MIBG formulation that may produce undesirable side effects and reduce efficacy.  In addition, Ultratrace maximizes delivery of therapeutic radiation to tumors. 

"Azedra exemplifies Molecular Insight's strategy to apply its radiochemistry expertise to improve an existing therapy. Current targeted radiotherapies for cancer suffer from sub-optimal radiochemistry, which leads to an excess of non-therapeutic, cold contaminant molecules administered to patients. These cold contaminants compete for tumor binding and reduce the amount of therapeutic radiopharmaceutical that can bind the cancer cells. Our proprietary Ultratrace technology eliminates the presence of cold contaminants, creating a product that contains only radiolabeled molecules," said John W. Babich, President and CSO of Molecular Insight. "We believe that this ultrapurity, or lack of cold contaminants, produces optimal tumor uptake and efficacy."
 
Read more about Molecular Insight Pharmaceuticals' expertise in radiochemistry:
www.molecularinsight.com

 

The Marine Corps Marathon is the largest marathon in the world that does not offer prize money, earning its nickname, "The People's Marathon."  The beautiful scenic course runs through the nation's capital and is nicknamed, "The Marathon of the Monuments."

 

Every dollar raised will directly fund cutting-edge carcinoid and NET research.  Run to a cure!

To register please go to:
CFCF MCM Registration

 

Visit Team CFCF page

* No Federal or Marine Corps endorsement applied

 
Stay tuned for more updates on Ruth as she continues to share her story to promote awareness of carcinoid and the need for research. 

The Board of Patient Advisors provides CFCF with advice about how to support patients and partner in the fight against carcinoid.

Visit CFCF's Board of Patient Advisors page

Donate to CFCF

It is estimated that between 50,000 - 100,000 people are currently diagnosed with carcinoid.  $10 a year from each patient results in $500,000 - $1,000,000 of annual research funding.  Give up Starbucks for one week each year & change your life!